The market for isocitrate dehydrogenase (IDH) inhibitors worldwide has a market value of US$ 1.7 billion in 2022 and is anticipated to grow at a CAGR of 33% from 2023 to 2033 to reach US$ 39.16 billion.

Additionally, the development of more potent and selective IDH inhibitors, as well as the expansion of their use into other cancer types, is expected to further contribute to the growth of the market. Bayer and Agios Pharmaceuticals are among the key players in the IDH inhibitors market, with their respective drugs BAY 1436032 and ivosidenib being approved by the US FDA for the treatment of IDH-mutated cancers. These drugs have shown promising results in clinical trials, including high response rates and extended survival in patients with AML.

The IDH inhibitors market is a rapidly growing field with significant potential for the treatment of several types of cancer. Continued research and development efforts, as well as the development of new drugs and treatment strategies, are expected to contribute to the growth of the market.

Unlock valuable insights today. Grab our sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16847

Key Takeaways:

• The global Isocitrate dehydrogenase (IDH) inhibitors market is expected to grow with a 33% CAGR during 2023 to 2033.
• Oral route of administration is expected to hold 49% of the market share in 2023 for Isocitrate dehydrogenase (IDH) inhibitors market.
• North America is expected to possess 46% market share for Isocitrate dehydrogenase (IDH) inhibitors market in 2023.
• Europe Isocitrate dehydrogenase (IDH) inhibitors market size is expected to possess 43% market share in 2023.

“The development of combination therapies and alternative treatment strategies is being explored to further optimize the clinical benefit of IDH inhibitors. This, in turn, is fueling the growth of IDH inhibitors market.” states an FMI analyst

Competitive Landscape:

Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.

• Bayer is collaborating with other pharmaceutical companies, such as Agios Pharmaceuticals, in the development of IDH inhibitors. The two companies have a joint development and commercialization agreement for ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme, which has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
• Agios’ Pharma lead IDH inhibitor candidate is ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme. Ivosidenib works by inhibiting the production of the oncometabolite 2-hydroxyglutarate (2-HG) and inducing differentiation of leukemia cells. Ivosidenib has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.

Key Segments:

Type:

• IDH1 Mutant Medullary Malignant Tumor
• IDH2 Mutant Medullary Malignant Tumor
• Peptides
• Small Molecule
• Others

Molecule Types:

• Monoclonal Antibody
• Peptides
• Small Molecules
• Others

Route of Administration:

• Oral
• Parenteral
• Subcutaneous